GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
R

Regen BioPharma RGBP · USD

N/A · US listing · 🇺🇸 United States

Compare

0.00

+33.33%

Close of 5 Nov 2026, in USD

About Regen BioPharma

From its filings with the US Securities and Exchange Commission

SEC filings

Regen BioPharma is based in La Mesa, California and is incorporated in Nevada. Its shares trade on OTC under the ticker RGBP. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 30 September 2025, it reported revenue of $236,561 and a net loss of $1.3m. At that date it held total assets of $274,628 and shareholders' equity of −$6.3m.

Read the filing on SEC.gov ↗

Company facts

Sector
N/A
Industry
N/A
Listed since
3 Sept 2014
Employees
1
Head office
4700 SPRING ST #304, LA MESA, CA, 91942
Incorporated in
NV
Classification
Pharmaceutical Preparations
Filer status
Non-accelerated filer<br>Smaller reporting company

Leadership

Pay as last reported

  • Dr. David KoosChairman of the Board, President, Chief Executive Officer, Treasurer, Secretary, since 2013$10,050

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Regen BioPharma focuses on innovative mRNA and small molecule therapies for cancer and autoimmune disorders.
  • Regen BioPharma develops HemaXellerate for personalized blood production stimulation in patients.
  • Regen BioPharma utilizes patented molecular targeting approaches like BORIS for cancer stem cell processes.

Weaknesses

  • Regen BioPharma has only one full-time employee, limiting operational capacity.
  • Regen BioPharma's clinical trials are limited to Phase I/II stages, indicating early development.
  • Regen BioPharma's IPO in 2014 shows limited market traction and growth.

Opportunities

  • Regen BioPharma can expand its mRNA therapy applications to new cancer types.
  • Regen BioPharma can leverage its DiffronC for blood disorder treatments in emerging markets.
  • Regen BioPharma can advance its cellular immunotherapy products like dCellVax to Phase III trials.

Threats

  • Regen BioPharma faces competition from established biotech firms in immunotherapy space.
  • Regen BioPharma's reliance on early-stage clinical trials poses regulatory approval risks.
  • Regen BioPharma's small team size increases vulnerability to operational disruptions.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.